← Back to Clinical Trials
Recruiting Phase 1 NCT05152290
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for SCI
Trial Parameters
Condition Spinal Cord Injuries
Sponsor The Foundation for Orthopaedics and Regenerative Medicine
Study Type INTERVENTIONAL
Phase Phase 1
Enrollment 20
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2022-07-06
Completion 2026-01
Interventions
AlloRx
Brief Summary
This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Spinal Cord Injury.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Spinal Cord Injury * Understanding and willingness to sign a written informed consent document Exclusion Criteria: * Active infection * Active cancer * Chronic multisystem organ failure * Pregnancy * Clinically significant Abnormalities on pre-treatment laboratory evaluation * Medical condition that would (based on the opinion of the investigator) compromise patient's safety. * Continued drug abuse * Pre-menopausal women not using contraception * Previous organ transplant * Hypersensitivity to sulfur * Anticoagulation medicine use